Interventions for Tuberculosis Control and Elimination 2002

Harm / protection (%)
20
0
-20
-40
-60
-80
-100
-120
-140
Protection
Harm
0.0 2.5 5.0 7.5 10.0 12.5 15.0
Year of follow-up
Figure 69. Protection from BCG vaccination in Chingleput, India during followup.
765
Canadian Indians
Chile
Per cent protection
Protection conferred by BCG vaccination across various age groups
Of the seven clinical trials studying protective efficacy across a wide range
of age groups, with a preponderance of persons other than infants, two
showed a high level of protection, of around 80%, while all of the others
showed little or no protection (figure 71). 738,763-765,767,768,781-787
These observations reconfirm that utilization of BCG vaccination in
age groups other than infants is rarely an effective intervention.
One retrospective study from the Gambia reported that 35 patients
among 200 without a BCG scar died during chemotherapy, while none of
114
Any age
Case-control
Adults
Case-control
-400 -100 0 30 50 80 90 95
Figure 70. Results from retrospective studies on the efficacy of BCG vaccination
against tuberculosis in adults. 779,780